Advanced Tumor Clinical Trial
Official title:
A Phase I/IIa Study to Evaluate the Tolerance, Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of PM1032 in Patients With Advanced Solid Tumors
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1032 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose（RP2D） of PM1032.
PM1032 is a Bispecific Antibody Targeting CLDN18.2 and 4-1BB. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05108779 -
QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05607563 -
A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours
|
Phase 1 | |
| Completed |
NCT02977156 -
Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT00502060 -
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
|
Phase 1 |